Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Significant Growth in Short Interest

Key Points

• Short interest jumped by 74.5% in March to 216,042 shares as of March 31, giving a short-interest ratio of about 0.1 days based on average daily volume.
• Analyst sentiment is mixed but tilted positive overall—MarketBeat shows an average rating of "Moderate Buy" (2 Strong Buy, 5 Buy, 1 Hold, 1 Sell) with recent upgrades from UBS and Barclays and a downgrade from Zacks.
• Stock snapshot: the ADR opened at $11.75, trades in a 1‑year range of $5.70–$14.85, has a market cap of $46.18B and a negative P/E of -10.59, with FY 2026 EPS guidance of 1.251–1.400 (consensus ~1.31).

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 216,042 shares, an increase of 74.5% from the March 15th total of 123,788 shares. Based on an average daily volume of 1,661,362 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company's shares are short sold.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. DZ Bank raised Bayer Aktiengesellschaft from a "strong sell" rating to a "hold" rating in a research report on Thursday. UBS Group upgraded Bayer Aktiengesellschaft from a "neutral" rating to a "buy" rating in a research note on Monday, March 16th. Barclays upgraded Bayer Aktiengesellschaft from an "equal weight" rating to an "overweight" rating in a research note on Tuesday, January 6th. Finally, Zacks Research downgraded Bayer Aktiengesellschaft from a "hold" rating to a "strong sell" rating in a research note on Tuesday, March 24th. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Bayer Aktiengesellschaft presently has an average rating of "Moderate Buy".

Bayer Aktiengesellschaft Stock Performance

OTCMKTS:BAYRY opened at $11.75 on Monday. Bayer Aktiengesellschaft has a 1 year low of $5.70 and a 1 year high of $14.85. The stock's fifty day moving average price is $12.03 and its two-hundred day moving average price is $10.47. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.01 and a quick ratio of 0.63. The company has a market cap of $46.18 billion, a P/E ratio of -10.59 and a beta of 0.70.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last issued its quarterly earnings data on Wednesday, March 4th. The company reported $0.18 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.18. Bayer Aktiengesellschaft had a positive return on equity of 15.93% and a negative net margin of 8.51%.The company had revenue of $13.24 billion for the quarter, compared to the consensus estimate of $13.08 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. As a group, analysts expect that Bayer Aktiengesellschaft will post 1.31 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women's health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.